$17.36
Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
BMO Capital Initiates Trevi Therapeutics at Outperform With $36 Price Target
B. Riley Adjusts Trevi Therapeutics Price Target to $31 From $21, Maintains Buy Rating
Trevi Therapeutics (TRVI) Soars as Haduvio Taps Into $15B Addressable Market
Overview
52-week range
$5.41
$16
100% of range
Avg surprise (last 3)
+4.1%
Avg reaction (last 2)
+0.5%
50% positive
Latest IV / EM
58%
EM ±13.2% · $17 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 5, 2026 | Mar/2026 | $-0.09 | $-0.07 | -28.6% | 0.0% | +1.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.08 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-0.09 | $-0.10 | +10.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.09 | $-0.13 | +30.8% | — | -0.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.13 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.12 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.11 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.08 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.07 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$0.11 | -$0.09 | -22.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-15M | — | $-14M | $-14M | $-11M | — | $-14M | $-13M |
| Net income | $-13M | — | $-12M | $-12M | $-10M | — | $-13M | $-12M |
| EPS (diluted) | $-0.09 | — | $-0.08 | $-0.09 | $-0.09 | — | $-0.13 | $-0.12 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $19M | $19M | $57M | $117M | $19M | $34M | $16M | $13M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $176M | $192M | $198M | $207M | $106M | $109M | $67M | $72M |
| Total assets | $180M | $193M | $199M | $208M | $107M | $111M | $69M | $74M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $7M | $10M | $10M | $10M | $8M | $11M | $10M | $8M |
| Total equity | $172M | $183M | $190M | $198M | $99M | $100M | $59M | $66M |